Presentation is loading. Please wait.

Presentation is loading. Please wait.

Discordant HER2 Exon 20 Mutation Status Determines a Differential Sensitivity to Afatinib  Chien-Hung Gow, MD, PhD, Wei-Yu Liao, MD, PhD, Yi-Nan Liu,

Published byThéophile Ducharme Modified over 5 years ago

Similar presentations

Presentation on theme: "Discordant HER2 Exon 20 Mutation Status Determines a Differential Sensitivity to Afatinib  Chien-Hung Gow, MD, PhD, Wei-Yu Liao, MD, PhD, Yi-Nan Liu,"— Presentation transcript:

1 Discordant HER2 Exon 20 Mutation Status Determines a Differential Sensitivity to Afatinib 
Chien-Hung Gow, MD, PhD, Wei-Yu Liao, MD, PhD, Yi-Nan Liu, PhD, Jin-Yuan Shih, MD, PhD  Journal of Thoracic Oncology  Volume 10, Issue 7, Pages e58-e60 (July 2015) DOI: /JTO Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

2 FIGURE 1 A, B, Sequencing of exon 20 of HER2 reveals GGCTCCCCA insertion (P780_Y781insGSP; red font) in the primary lung tumor, although exon 20 in the metastatic brain tumor is wild-type. C, D, Computed tomography images show the patient’s lungs and brain after the failure of several chemotherapy agents, and before afatinib treatment. E, F, Computed tomography images of the patient’s lungs and brain show a significant response to afatinib treatment after 3 months in the primary right lower lung tumor, and disease progression in the right metastatic cerebellar tumor. Journal of Thoracic Oncology  , e58-e60DOI: ( /JTO ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

3 FIGURE 2 A, Enhancing HER2 phosphorylation in Ba/F3 cells expressed the HER2 mutants. Whole cell lysates from H1299 (expressing wild-type HER2, as a control) and Ba/F3 cells expressing different HER2 mutants were collected for the detection of ErbB2, phospho-ErbB2 (p-ErbB2), and α-tubulin was used as loading controls. Data shown are representative of three independent experiments that yielded similar results. The p-ErbB2/ErbB2 ratio was similar in both HER2 mutants expressing cells, but was very low in wild-type HER2 expressing cells. B, Afatinib-dependent growth inhibition in Ba/F3 cells expressed the HER2 mutant. Ba/F3 cells expressing mutant P780_Y781insGSP or A775_G776insYVMA growing in the absence of interleukin-3, or expressing vector in the presence of interleukin-3 (as a control) were incubated with the indicated concentrations of afatinib for 72 hours. Cell viability was measured using the 3-(4,5-cimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide assay. Points Average of two experiments (each performed in triplicate); bars standard deviation. Journal of Thoracic Oncology  , e58-e60DOI: ( /JTO ) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Discordant HER2 Exon 20 Mutation Status Determines a Differential Sensitivity to Afatinib  Chien-Hung Gow, MD, PhD, Wei-Yu Liao, MD, PhD, Yi-Nan Liu,"

Similar presentations

Alpha-Actinin 4 Is Associated with Cancer Cell Motility and Is a Potential Biomarker in Non–Small Cell Lung Cancer  Ming-Chuan Wang, PhD, Ying-Hua Chang,

Alpha-Actinin 4 Is Associated with Cancer Cell Motility and Is a Potential Biomarker in Non–Small Cell Lung Cancer  Ming-Chuan Wang, PhD, Ying-Hua Chang,
A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.

A Case of a Patient with Idiopathic Pulmonary Fibrosis with Lung Squamous Cell Carcinoma Treated with Nivolumab  Monica Khunger, MD  Journal of Thoracic.
Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA  Tomomi Nakamura, MD, Naoko Sueoka-Aragane,

Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA  Tomomi Nakamura, MD, Naoko Sueoka-Aragane,
Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.

Comparison of Clinical Outcomes Following Gefitinib and Erlotinib Treatment in Non– Small-Cell Lung Cancer Patients Harboring an Epidermal Growth Factor.
The Epidermal Growth Factor Receptor-L861Q Mutation Increases Kinase Activity without Leading to Enhanced Sensitivity Toward Epidermal Growth Factor Receptor.

The Epidermal Growth Factor Receptor-L861Q Mutation Increases Kinase Activity without Leading to Enhanced Sensitivity Toward Epidermal Growth Factor Receptor.
Intramedullary Spinal Cord Hemorrhage after Treatment with Bevacizumab in a Long- term Survivor with Metastatic Non–Small-Cell Lung Cancer  Kristin N.

Intramedullary Spinal Cord Hemorrhage after Treatment with Bevacizumab in a Long- term Survivor with Metastatic Non–Small-Cell Lung Cancer  Kristin N.
Next Generation Sequencing Uncovers Potential Genetic Driver Mutations of Malignant Pulmonary Granular Cell Tumor  Song Xu, Qingchun Zhao, Sen Wei, Yi.

Next Generation Sequencing Uncovers Potential Genetic Driver Mutations of Malignant Pulmonary Granular Cell Tumor  Song Xu, Qingchun Zhao, Sen Wei, Yi.
Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA  Tomomi Nakamura, MD, Naoko Sueoka-Aragane,

Application of a Highly Sensitive Detection System for Epidermal Growth Factor Receptor Mutations in Plasma DNA  Tomomi Nakamura, MD, Naoko Sueoka-Aragane,
Pathway Targeted Immunotherapy: Rationale and Evidence of Durable Clinical Responses with a Novel, EGF-directed Agent for Advanced NSCLC  Rafael Rosell,

Pathway Targeted Immunotherapy: Rationale and Evidence of Durable Clinical Responses with a Novel, EGF-directed Agent for Advanced NSCLC  Rafael Rosell,
Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 

Hironori Yoshida, MD, Young Hak Kim, MD  Journal of Thoracic Oncology 
Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD  Journal of Thoracic Oncology 

Chia-Lin Hsu, MD, Kuan-Yu Chen, MD, PhD  Journal of Thoracic Oncology 
EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients  Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin.

EGFR Array: Uses in the Detection of Plasma EGFR Mutations in Non–Small Cell Lung Cancer Patients  Irene Yam, BSc, David Chi-Leung Lam, MBBS, PhD, Kaimin.
Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.
Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer

Abscopal Effect of Nivolumab in a Patient with Primary Lung Cancer
Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.

Malignant Pleural Mesothelioma Harboring Both G719C and S768I Mutations of EGFR Successfully Treated with Afatinib  Nobukazu Agatsuma, MD  Journal of.
Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation  Alessandro Russo, MD, Tindara.

Rapid Acquisition of T790M Mutation after Treatment with Afatinib in an NSCLC Patient Harboring EGFR Exon 20 S768I Mutation  Alessandro Russo, MD, Tindara.
Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib  Chao-Chi Ho, MD, PhD, Wei-Yu Liao, MD, PhD, Chih-An Lin, Jin-Yuan.

Acquired BRAF V600E Mutation as Resistant Mechanism after Treatment with Osimertinib  Chao-Chi Ho, MD, PhD, Wei-Yu Liao, MD, PhD, Chih-An Lin, Jin-Yuan.
Radiotherapy Rescue of a Nivolumab-Refractory Immune Response in a Patient with PD-L1–Negative Metastatic Squamous Cell Carcinoma of the Lung  Zhigang.

Radiotherapy Rescue of a Nivolumab-Refractory Immune Response in a Patient with PD-L1–Negative Metastatic Squamous Cell Carcinoma of the Lung  Zhigang.
Subclonal Therapy by Two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR-Mutated Lung Cancer  Nir Peled, MD, PhD, Laila C. Roisman, PhD, Benjamin.

Subclonal Therapy by Two EGFR TKIs Guided by Sequential Plasma Cell-free DNA in EGFR-Mutated Lung Cancer  Nir Peled, MD, PhD, Laila C. Roisman, PhD, Benjamin.
Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non–Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy  Sotirios Lakis,

Detection of Discrepant Driver Mutations in a Patient with Two Synchronous Primary Non–Small Cell Lung Cancers (NSCLCs) with Liquid Biopsy  Sotirios Lakis,

Similar presentations

Ads by Google